Overview
- 5 inspections across 5 sites are on record.
- 10 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2020-02-28.
At a glance
Inspections
5
Sites
5
Observations
10
Career since
Sep 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Biomarin Pharmaceutical, Inc. | 28 Feb 2020 | Human Drugs | View 483 → |
| Aveva Drug Delivery Systems Inc. | 26 Jul 2019 | Human Drugs | View 483 → |
| Shire Human Genetic Therapies, Inc. | 25 Jul 2018 | Human Drugs | On file |
| Sanofi Genzyme | 14 Sep 2017 | Human Drugs | |
| Amgen, Inc. | 1 Sep 2016 | Human Drugs |
Sites inspected
Biomarin Pharmaceutical, Inc.San Rafael, United States1 insp.
Aveva Drug Delivery Systems Inc.Miramar, United States1 insp.
Shire Human Genetic Therapies, Inc.Lexington, United States1 insp.
Sanofi GenzymeAllston, United States1 insp.
Amgen, Inc.Thousand Oaks, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Dipti Kalra2 shared
Dustin P Tran1 shared
Stephen T Hansen1 shared
Karen M Montgomery1 shared
Youmin Wang1 shared
Richard A Lyght1 shared
Jennifer Lalama1 shared
Byungja E Marciante1 shared
Michael P Anthony1 shared
Hugh M Mcclure1 shared
Full investigator report
Get the verbatim findings behind Haley H Seymour's 10 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site